利用真实生活数据库(国家健康数据系统 - SNDS)--CaPCo 研究,分析 2010 年至 2021 年法国前列腺癌的发病率和死亡率。

IF 2.8 2区 医学 Q2 UROLOGY & NEPHROLOGY World Journal of Urology Pub Date : 2024-10-28 DOI:10.1007/s00345-024-05291-9
Hugo Crespin, Anne-Isabelle Lecuyer, Emeline Laurent, Franck Bruyere, Leslie Grammatico-Guillon
{"title":"利用真实生活数据库(国家健康数据系统 - SNDS)--CaPCo 研究,分析 2010 年至 2021 年法国前列腺癌的发病率和死亡率。","authors":"Hugo Crespin, Anne-Isabelle Lecuyer, Emeline Laurent, Franck Bruyere, Leslie Grammatico-Guillon","doi":"10.1007/s00345-024-05291-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Prostate cancer (PCa) was the leading incident cancer and 3rd leading cause of cancer death in men in France in 2015 with inter-regional disparities. The objectives were to describe PCa incidence and mortality in France and by region, using real life data from the National Health Data System and to identify the factors associated with all-cause or PCa-specific mortality.</p><p><strong>Methods: </strong>Men aged ≥ 18years hospitalized and/or on long-term care for PCa (ICD-10 code C61) in France between 2010 and 2021 were included. An incident case was defined by the absence of any cancer in the five years preceding the first coding. Incidence and mortality estimates were age-standardized: France 2018f standardized rates (FSR), all-cause mortality (SMR) and PCa-specific mortality (SMRspe). Factors associated with death were identified using cause-specific Cox models.</p><p><strong>Results: </strong>The mean annual incidence was 47,081cases/year (FSR:179.6/100,000men), increasing over the period except 2020. All-cause mortality was 20,259 deaths/year (77.3/100,000men), and PCa-specific mortality was 7,265 deaths/year (27.7/100,000men). A PCa-specific mortality excess was found in Centre-Val-de-Loire (SMRspe = 1.21), Bretagne (1.18), Hauts-de-France (1.17) Normandie (1.15). After adjustment, significant PCa mortality excess was observed in Bretagne (HR = 1,29;<sub>95%</sub>IC[1.09-1.46]) and Hauts-de-France (HR = 1.19[1.03-1.34]). The other factors associated with death were an age ≥ 60years, an increasing comorbidity index, metastatic disease at onset (major weight in specific mortality with hazard ratio HR = 16.1[15.2-17.0]), precariousness, affiliation to the agricultural scheme, and the COVID period in all-cause mortality.</p><p><strong>Conclusion: </strong>This study updated incidence and mortality data in France. It showed differences in mortality between regions in France. The adjustment moderates regional findings based on raw mortality data.</p>","PeriodicalId":23954,"journal":{"name":"World Journal of Urology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Incidence and mortality of prostate cancer in France from 2010 to 2021, using a real-life database (National Health Data System - SNDS) - the CaPCo Study.\",\"authors\":\"Hugo Crespin, Anne-Isabelle Lecuyer, Emeline Laurent, Franck Bruyere, Leslie Grammatico-Guillon\",\"doi\":\"10.1007/s00345-024-05291-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>Prostate cancer (PCa) was the leading incident cancer and 3rd leading cause of cancer death in men in France in 2015 with inter-regional disparities. The objectives were to describe PCa incidence and mortality in France and by region, using real life data from the National Health Data System and to identify the factors associated with all-cause or PCa-specific mortality.</p><p><strong>Methods: </strong>Men aged ≥ 18years hospitalized and/or on long-term care for PCa (ICD-10 code C61) in France between 2010 and 2021 were included. An incident case was defined by the absence of any cancer in the five years preceding the first coding. Incidence and mortality estimates were age-standardized: France 2018f standardized rates (FSR), all-cause mortality (SMR) and PCa-specific mortality (SMRspe). Factors associated with death were identified using cause-specific Cox models.</p><p><strong>Results: </strong>The mean annual incidence was 47,081cases/year (FSR:179.6/100,000men), increasing over the period except 2020. All-cause mortality was 20,259 deaths/year (77.3/100,000men), and PCa-specific mortality was 7,265 deaths/year (27.7/100,000men). A PCa-specific mortality excess was found in Centre-Val-de-Loire (SMRspe = 1.21), Bretagne (1.18), Hauts-de-France (1.17) Normandie (1.15). After adjustment, significant PCa mortality excess was observed in Bretagne (HR = 1,29;<sub>95%</sub>IC[1.09-1.46]) and Hauts-de-France (HR = 1.19[1.03-1.34]). The other factors associated with death were an age ≥ 60years, an increasing comorbidity index, metastatic disease at onset (major weight in specific mortality with hazard ratio HR = 16.1[15.2-17.0]), precariousness, affiliation to the agricultural scheme, and the COVID period in all-cause mortality.</p><p><strong>Conclusion: </strong>This study updated incidence and mortality data in France. It showed differences in mortality between regions in France. The adjustment moderates regional findings based on raw mortality data.</p>\",\"PeriodicalId\":23954,\"journal\":{\"name\":\"World Journal of Urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00345-024-05291-9\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00345-024-05291-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:2015年,前列腺癌(PCa)是法国男性发病率最高的癌症,也是男性癌症死亡的第三大原因,但地区间存在差异。研究目的是利用国家健康数据系统(National Health Data System)提供的真实数据,按地区描述法国前列腺癌的发病率和死亡率,并确定与全因死亡率或前列腺癌特异性死亡率相关的因素:纳入2010年至2021年期间在法国因PCa(ICD-10代码C61)住院和/或接受长期治疗的年龄≥18岁的男性。首次编码前五年内未患任何癌症即为偶发病例。发病率和死亡率估计值已进行年龄标准化:法国2018六开彩开奖结果标准化率(FSR)、全因死亡率(SMR)和PCa特异性死亡率(SMRspe)。使用特定病因 Cox 模型确定了与死亡相关的因素:平均年发病率为 47,081 例/年(FSR:179.6/100,000 名男性),除 2020 年外,发病率一直在上升。全因死亡率为 20,259 例/年(77.3/100,000 人),PCa 特异死亡率为 7,265 例/年(27.7/100,000 人)。在卢瓦尔河中游省(SMRspe = 1.21)、布列塔尼省(1.18)、上法兰西省(1.17)和诺曼底省(1.15)发现 PCa 特异性死亡率超标。经调整后,布列塔尼省(HR = 1.29;95%IC[1.09-1.46])和上法兰西省(HR = 1.19[1.03-1.34])的 PCa 死亡率明显偏高。与死亡相关的其他因素包括:年龄≥60岁、合并症指数增加、发病时患有转移性疾病(在特定死亡率中占主要权重,危险比HR=16.1[15.2-17.0])、不稳定、隶属于农业计划以及全因死亡率中的COVID时期:这项研究更新了法国的发病率和死亡率数据。结论:这项研究更新了法国的发病率和死亡率数据,显示了法国不同地区之间的死亡率差异。调整结果缓和了基于原始死亡率数据的地区调查结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Incidence and mortality of prostate cancer in France from 2010 to 2021, using a real-life database (National Health Data System - SNDS) - the CaPCo Study.

Background and objective: Prostate cancer (PCa) was the leading incident cancer and 3rd leading cause of cancer death in men in France in 2015 with inter-regional disparities. The objectives were to describe PCa incidence and mortality in France and by region, using real life data from the National Health Data System and to identify the factors associated with all-cause or PCa-specific mortality.

Methods: Men aged ≥ 18years hospitalized and/or on long-term care for PCa (ICD-10 code C61) in France between 2010 and 2021 were included. An incident case was defined by the absence of any cancer in the five years preceding the first coding. Incidence and mortality estimates were age-standardized: France 2018f standardized rates (FSR), all-cause mortality (SMR) and PCa-specific mortality (SMRspe). Factors associated with death were identified using cause-specific Cox models.

Results: The mean annual incidence was 47,081cases/year (FSR:179.6/100,000men), increasing over the period except 2020. All-cause mortality was 20,259 deaths/year (77.3/100,000men), and PCa-specific mortality was 7,265 deaths/year (27.7/100,000men). A PCa-specific mortality excess was found in Centre-Val-de-Loire (SMRspe = 1.21), Bretagne (1.18), Hauts-de-France (1.17) Normandie (1.15). After adjustment, significant PCa mortality excess was observed in Bretagne (HR = 1,29;95%IC[1.09-1.46]) and Hauts-de-France (HR = 1.19[1.03-1.34]). The other factors associated with death were an age ≥ 60years, an increasing comorbidity index, metastatic disease at onset (major weight in specific mortality with hazard ratio HR = 16.1[15.2-17.0]), precariousness, affiliation to the agricultural scheme, and the COVID period in all-cause mortality.

Conclusion: This study updated incidence and mortality data in France. It showed differences in mortality between regions in France. The adjustment moderates regional findings based on raw mortality data.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
World Journal of Urology
World Journal of Urology 医学-泌尿学与肾脏学
CiteScore
6.80
自引率
8.80%
发文量
317
审稿时长
4-8 weeks
期刊介绍: The WORLD JOURNAL OF UROLOGY conveys regularly the essential results of urological research and their practical and clinical relevance to a broad audience of urologists in research and clinical practice. In order to guarantee a balanced program, articles are published to reflect the developments in all fields of urology on an internationally advanced level. Each issue treats a main topic in review articles of invited international experts. Free papers are unrelated articles to the main topic.
期刊最新文献
The outcomes of robot-assisted surgery in the treatment of neurogenic lower urinary tract dysfunctions: a systematic review and meta-analysis. The role of re-transurethral resection of bladder tumor in patients with TaHG non muscle invasive bladder cancer. Ideal cystoscopic interval after nephroureterectomy in patients with upper tract urothelial carcinoma. Is flexible and navigable suction ureteral access sheath (FANS-UAS) the next best development for retrograde intrarenal surgery in children? Results of a prospective multicentre study. Letter to the editor for the article "The impact of non-structured PSA testing on prostate cancer-specific mortality on New Zealand Māori men".
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1